dermatology Archives -

Incyte’s Opzelura cream has become the first medical treatment approved to re-pigment the skin of people with vitiligo

FDA clears Incyte’s Opzelura as first vitiligo therapy

https://pharmaphorum.com/news/fda-clears-incytes-opzelura-as-first-vitiligo-therapy/

Almirall-backed psoriasis support app Claro launches in Europe

Phil Taylor Almirall, dermatology, digital, digital health, Happify, mental health, patient support, psoriasis 0 Comment

An alliance between Spanish drugmaker Almirall and digital health company Happify has yielded its first fruit, with the

Almirall-backed psoriasis support app Claro launches in Europe

https://pharmaphorum.com/news/almirall-backed-psoriasis-support-app-claro-launches-in-europe/

News/ News/ Sales and Marketing

FDA grants speedy review to Dupixent rare skin disease

Phil Taylor dermatology, Dupixent, prurigo nodularis, rare disease, Regeneron, regulatory, Sanofi 0 Comment

Sanofi and Regeneron should hear from the FDA in the autumn whether it will approve their blockbuster immunology

FDA grants speedy review to Dupixent rare skin disease

https://pharmaphorum.com/news/fda-grants-speedy-review-to-dupixent-rare-skin-disease/

Market Access/ News/ News

Third FDA rejection for Verrica’s molluscum contagiosum drug

Phil Taylor dermatology, drug devices, infectious disease, molluscum contagiosum, Verrica Pharmaceuticals, VP-102 0 Comment

Shares in US biotech Verrica Pharma lost half their value today after the FDA declined to approve its

Third FDA rejection for Verrica’s molluscum contagiosum drug

https://pharmaphorum.com/news/third-fda-rejection-for-verricas-molluscum-contagiosum-drug/

Market Access/ News/ News

Dermavant claims its first approval as FDA clears psoriasis drug

Phil Taylor dermatology, Dermavant, psoriasis, regulatory approval, tapinarof, Vtama 0 Comment

Roivant group company Dermavant has made the transition to a commercial-stage company after getting FDA approval for Vtama,

Dermavant claims its first approval as FDA clears psoriasis drug

https://pharmaphorum.com/news/dermavant-claims-its-first-approval-as-fda-clears-psoriasis-drug/

Digital/ News/ News

Sidekick and Pfizer prep launch of DTx for atopic dermatitis

Phil Taylor atopic dermatitis, dermatology, digital, digital health, digital therapeutics, Pfizer, Sidekick Health 0 Comment

A long-running partnership between digital therapeutics (DTx) developer Sidekick Health and Pfizer has resulted in a new app

Sidekick and Pfizer prep launch of DTx for atopic dermatitis

https://pharmaphorum.com/news/sidekick-and-pfizer-prep-launch-of-dtx-for-atopic-dermatitis/

Digital/ News/ News

Happify says study backs value of its wellbeing app in psoriasis

Phil Taylor app, dermatology, digital, digital health, Happify, mental health, psoriasis 0 Comment

People with psoriasis who used an app developed by digital health company Happify reported reduced anxiety and improvements

Happify says study backs value of its wellbeing app in psoriasis

https://pharmaphorum.com/news/happify-says-study-backs-value-of-its-wellbeing-app-in-psoriasis/

Market Access/ News/ News

FDA turns down Amryt’s epidermolysis bullosa drug

Phil Taylor Amryt Pharma, dermatology, epidermolysis bullosa, inherited disease, rare disease, regulatory 0 Comment

Amryt Pharma has been handed a major blow by the FDA, after the US regulator rejected its marketing

FDA turns down Amryt’s epidermolysis bullosa drug

https://pharmaphorum.com/news/fda-turns-down-amryts-epidermolysis-bullosa-drug/

News/ News/ R&D

Almirall and IRB Barcelona team up to tackle skin disease

Joy Persaud Almirall, dermatology, R&D, skin 0 Comment

Two Spanish pharma companies are joining forces to identify new oral treatments for immune-inflammatory skin diseases with high

Almirall and IRB Barcelona team up to tackle skin disease

https://pharmaphorum.com/news/almirall-irb-barcelona-team-up-to-tackle-skin-disease/

Trending

dermatology

Login